Sort
10,766 grants matching “checkpoint inhibitor”
Novel Targets for Immunotherapy
$1,363,673Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2022 · CA
Overcoming resistance to BRAF(V600E) targeted therapies in melanoma
$1,363,291David E Fisher · Massachusetts General Hospital · P01 · FY2014 · CA
Preclinical drug development in pancreatic cancer
$1,356,844Udo Rudloff · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Synthetic metabolism to armor and enhance a new class of cell therapies
$1,356,578John James Blazeck · Georgia Institute Of Technology · DP2 · FY2022 · CA
An integrated translational approach to overcome drug resistance
$1,356,228Ryan Bruce Corcoran · Massachusetts General Hospital · U54 · FY2020 · CA
SBIR Phase II: Anti-Tumor Immune Redirectors (AIRs) for cancer treatment
$1,355,844Joshua Wang · Verimmune Inc. · · FY2020 · TIP
Thoracic and Gastrointestinal Malignancies Branch Clinical Core
$1,350,761Raffit Hassan · Division Of Basic Sciences - Nci · ZID · FY2020 · CA
UNDERSTANDING THE IMMUNE BIOLOGY OF CHECKPOINT INHIBITORS TO DEVELOP NEW STRATEGIES FOR THERAPY
$1,348,203The Wistar Institute Of Anatomy And Biology · · FY2016 · Department of the Army
Effects of genetic polymorphism in MHC, KIR, and related loci on human disease
$1,345,829Mary N. Carrington · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Center for Interventional Oncology
$1,340,499Bradford J Wood · Division Of Basic Sciences - Nci · ZID · FY2023 · CA
Tumor Microenvironment in Cancer Progression
$1,339,057Rosandra Kaplan · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Therapeutic vaccination and PD-1 blockade in treated HIV disease
$1,336,452Steven Grant Deeks · University Of California, San Francisco · U01 · FY2021 · AI
Thoracic and Gastrointestinal Malignancies Branch Clinical Core
$1,336,014Raffit Hassan · Division Of Basic Sciences - Nci · ZID · FY2019 · CA
1/2 CCNY-MSK Partnership for Cancer Research, Education and Community Outreach
$1,334,500Karen Hubbard · City College Of New York · U54 · FY2024 · CA
1/2 CCNY-MSK Partnership for Cancer Research, Education and Community Outreach
$1,334,500Bao Q Vuong · City College Of New York · U54 · FY2025 · CA
Novel Targets for Immunotherapy
$1,330,078Claudia Palena · Division Of Basic Sciences - Nci · ZIC · FY2020 · CA
Novel Target, New Therapy: Anti- Renalase Antibody for Tumors Resistant to PD-1Inhibitors
$1,327,758Barry A Berkowitz · Bessor Pharma, Llc · R44 · FY2021 · CA
Studies of Receptor Interactions and Effects of Alarmins
$1,327,663Joost J Oppenheim · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma
$1,327,446Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Molecular Targets for Drug and Radiation Sensitivity
$1,326,588Stephen M Hahn · University Of Pennsylvania · P01 · FY2007 · CA
Therapeutic evaluation in ovarian and breast cancer GEMGDA models
$1,323,540Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Preclinical GEM and GDA Models of Primary and Metastatic Melanoma
$1,323,540Shyam Sharan · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Molecular Determinants of Chromosome Transmission and Cell Cycle Regulation
$1,323,228Munira Basrai · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Preclinical Mouse Models for Studying Immune Checkpoint Inhibitor Response
$1,318,085Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA
Genetically Engineered Mouse Models to Study Melanoma Genesis and Progression
$1,318,085Glenn T. Merlino · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA